ABSTRACT Bronchial hyperresponsiveness to inhaled histamine in smokers is associated with an accelerated annual decline in FEV, and low baseline FEV, values. The evolution of bronchial hyperresponsiveness and whether it precedes or follows the accelerated decline in FEV, and reduction in FEV, is unknown. Measurements of the provocative concentration of inhaled histamine required to reduce FEV, by 20% (PC20) were repeated after a four year interval in 27 male smokers (mean age 59 years, smoking on average 27 cigarettes a day in 1986) and 16 men who were ex-smokers in 1982 and who remained non-smokers until 1986 (mean age 53 years in 1986). These men were originally recruited to a prospective study in 1974 and had their first PC20 measurement in 1982. PC20 was positively related to baseline FEV, in both smokers and ex-smokers in both 1982 and 1986 (r ranging from 0-56 to 0 76, p < 0 01). In smokers mean FEV, fell from 83% to 77% predicted (p < 0-001) and geometric mean PC20 from 7 11 to 3-27 mg/ml (p < 0 001) between 1982 and 1986. The change in PC20 in individual smokers over the four years was related to change in FEV, (p = 0-012). In ex-smokers mean FEV, was 93% predicted both in 1982 and in 1986 and there was no significant difference in geometric mean PC20 between 1982 (6 68 mg/ml) and 1986 (5 98 mg/ml). Thus in smokers there was an accelerated annual decline in FEV, and an increase in bronchial hyperresponsiveness as FEV, fell.
Introduction
Longitudinal studies have shown that only a minority of cigarette smokers develop progressive deterioration of lung function sufficient to lead to appreciable disability.' More than 20 years ago Dutch workers proposed that susceptible smokers might be those individuals who showed non-specific bronchial hyperresponsiveness,2 and subsequent studies have shown that smokers with an accelerated decline in lung function show bronchial hyperresponsiveness to methacholine3 and histamine.4" Although these findings are consistent with the "Dutch hypothesis," they do not distinguish between this hypothesis and the possibility that the increased responsiveness is a consequence of accelerated decline in lung function. The natural history of established bronchial hyperresponsiveness in smokers and ex-smokers is unknown. In this paper we describe changes in FEV, and bronchial response to inhaled histamine between 1982 and 1986 in 27 men who continued to smoke and in 16 male ex-smokers who continued not to smoke.
Methods

SUBJECTS
The men studied were originally recruited to a prospective study of lung function in 19746 and at that time any who gave a history of asthma were excluded. In 1982 the bronchial response to inhaled histamine was assessed for the first time. 4 Of 223 men tested in 1982, 42 cigarette smokers and 23 ex-smokers had a provocative concentration of histamine that 599 600 reduced FEVY by 20% (PC20) of less than 32 mg/mi. In 1986 we restudied baseline FEV, and bronchial response to histamine in all the available men who had had a PC20 below 32 mg/ml in 1982 and who had maintained consistent smoking habits in the interval-a total of 27 continuing cigarette smokers and 16 ex-smokers who had already stopped smoking in 1982 and had not resumed smoking in the years before our repeat study in 1986. Of the 15 smokers studied in 1982 who were not restudied in 1986, two had died of bronchogenic carcinoma, five had stopped smoking or switched to cigars or pipes, and eight refused to be restudied. Four men who had stopped smoking in 1982 had resumed in 1986 and three exsmokers in 1982 declined to be restudied. Reported smoking habits were confirmed by several measurements of the fractional concentration of carbon monoxide in mixed expired gas and plasma cotinine concentrations. Subjects were not studied within six weeks of an upper or lower respiratory tract infection. None of the men was receiving bronchodilator treatment.
MEASUREMENTS
The men were studied between 09 00 and 12 00 hours, after first responding to a questionnaire regarding smoking habits and respiratory symptoms. Venous blood was drawn for measurement of total white blood cell counts, eosinophil counts, and total IgE levels. Skin reactivity to extracts from nine commonly inhaled antigens (grass pollen, cat and dog dander, mixed feathers, Alternaria sp, Cladosporium sp, Aspergillus fumigatus, house dust, and Dermatophagoides pteronyssinus) was assessed by prick tests in forearm skin. The response to the test was recorded as positive when the mean weal diameter was over 2 mm. Technical details of these measurements have been described.7
Forced expiratory volume in one second (FEV,) of the lowest post-saline value or the 32 mg/ml concentration of histamine was reached. The PC20 histamine was obtained by linear interpolation from a log dose-response curve.
ANALYSIS
The annual decline in height corrected FEV, (ml/m3/y) between the two measurements of histamine response was calculated by subtracting the highest baseline value recorded in 1986 from the highest value in 1982 and dividing by the cube of the height in metres.' Because four year estimates of change in FEV, have a relatively low signal to noise ratio, we also calculated the annual change in FEV, between 1974 and 1986, using the highest baseline value obtained in 1974. All PC20 and IgE values were logarithmically transformed before analysis, and geometric mean values were derived. Student's t test was used to compare group mean values and to determine differences in paired observations between and within groups. The change in PC20 (APC20) in an individual was regressed on the change in FEVY to obtain the relationship between trends in the two measurements over the four years. P values below 0-05 were considered statistically significant.
Results
In 1986 the mean (SEM) reported cigarette consumption for smokers was 27 (2 5) per day. The ex-smokers who had stopped smoking for a mean period of 11 (2) years and a minimum of 5 (r = -0-481, p < 0-02). In ex-smokers the annual decline in FEV, over 12 years was somewhat greater than the decline during 1982-6. This was expected as in the early years of follow up some individuals were smoking.
Discussion
Since the first descriptions in the 1960s22 many studies have confirmed that smokers with some degree of airflow obstruction but without evidence of atopy show bronchial hyperresponsiveness to inhaled histamine and methacholine. Moreover, smokers with bronchial hyperresponsiveness are known to have had a faster annual decline in FEVY than smokers without hyperresponsiveness.35 A reduced FEVY, however, is an important association of a low PC20 in smokers4 13-16 and it is also commonly associated with a preceding accelerated decline of FEV, ("horseracing effect"). '4 Because of these close interrelations between baseline FEV,, bronchial hyperresponsiveness, and rate of decline in FEV, it is uncertain whether hyperresponsiveness is important in the pathogenesis of progressive airflow obstruction in smokers or merely a consequence of its development, analogous to the development of increased vascular reactivity in hypertension."
In this study we have shown that smokers and exsmokers who had bronchial hyperresponsiveness in 1982 still had it in 1986. Over the four years there was an association between accelerated decline in FEV, and reduction in PC20 in smokers, whereas in exsmokers there was only the predicted age related decline in FEV, and no change in mean PC20. As 
expected from our earlier analysis of the larger group that contained these men in 1982,4 baseline FEV, was correlated with PC20, in both smokers and ex-smokers. Similar correlations were found in the 1986 results. These results confirm those of many other investigators who have studied patients with "chronic obstructive pulmonary disease" or middle aged smokers45 1316; this relation is much less consistent in asthma. 18 Our new finding is that as a group smokers showed a significant decline in PC20 over the four years' follow up and that in individual smokers the extent of decline in PC20 was related to the rate of annual decline in FEV,. Because we first measured bronchial responsiveness in these men when they had already smoked for many years and often had some degree of airflow obstruction, we cannot conclude that bronchial hyperresponsiveness followed rather than preceded the development of airflow obstruction in 1982, but our follow up results strongly indicate that airway geometry plays an important part in determining hyperresponsiveness. We believe that the results in ex-smokers also support this conclusion. In the ex-smokers, although on average FEV, in 1982 was slightly below expected values, over the following four years there was only the predicted age related further decline, so that the mean FEV, value was 93% of the predicted value in both 1982 and 1986. Despite this normal rate of decline in FEV, on average there was no attenuation of bronchial hyperresponsiveness. Because inflammatory changes, as indicated by white blood cell counts,7 cell counts from bronchoalveolar lavage fluid,'9 and sputum volume,20 are usually reduced after stopping smoking, we interpret the overall lack of change in PC20 in ex-smokers as emphasising the role of geometric rather than inflammatory changes in determining PC20 in smokers.
In the only other follow up studies of bronchial hyperresponsiveness in smokers we have identified, Simonsson and Rolf 2' also found no attenuation of bronchoconstrictor responsiveness in two mildly responsive men in the first year after stopping smoking, while Buckzo et al 22 found no change in methacholine responsiveness in 17 smokers 99 days on average after they reported stopping smoking.
When our longitudinal study started in 1974 we excluded men who gave a history of asthma or were receiving bronchodilator treatment.6 Subsequently we have analysed the significance of atopic factors (positive skin test responses to common inhalant allergens, a family history of asthma or rhinitis, raised total blood IgE and peripheral blood eosinophil counts) in the recruited men47 and found an increased prevalence of positive skin responses in ex-smokers. This, together with a higher mean value for total blood IgE, was also found in the present subgroup of exsmokers ( 
